Skip to main content

Gut Microbiota

1
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
Pembrolizumab Combined With ChemotherapyPhase 1/21 trial
Active Trials
NCT04333004Unknown40Est. Apr 2022
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Resistant Starch WheatN/A1 trial
Active Trials
NCT03082131Completed36Est. Apr 2019
Lonza
LonzaBasel, Switzerland
1 program
arabinogalactanN/A1 trial
Active Trials
NCT04351841Completed30Est. Dec 2019
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Casein hydrolysate added with LGGPHASE_41 trial
Active Trials
NCT01148667Completed40Est. Jul 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Johnson & JohnsonCasein hydrolysate added with LGG
UNION therapeuticsPembrolizumab Combined With Chemotherapy
Lonzaarabinogalactan
Human BioSciencesResistant Starch Wheat

Clinical Trials (4)

Total enrollment: 146 patients across 4 trials

NCT01148667Johnson & JohnsonCasein hydrolysate added with LGG

Lactobacillus Rhamnosus GG: Interaction With Human Microbiota and Immunity

Start: Mar 2007Est. completion: Jul 200840 patients
Phase 4Completed
NCT04333004UNION therapeuticsPembrolizumab Combined With Chemotherapy

Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

Start: Apr 2020Est. completion: Apr 202240 patients
Phase 1/2Unknown
NCT04351841Lonzaarabinogalactan

To Investigate the Effect of Arabinogalactan on the Gut Microbiome in Adults

Start: Aug 2019Est. completion: Dec 201930 patients
N/ACompleted
NCT03082131Human BioSciencesResistant Starch Wheat

Resistant Starch Wheat for Improved Metabolic Health

Start: May 2017Est. completion: Apr 201936 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.